Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase IIa Study to Investigate BL-8040 in Combination with Pembrolizumab in Patients with Metastatic Pancreatic Cancer

Next Previous
X
Search
Trial Profile

A Phase IIa Study to Investigate BL-8040 in Combination with Pembrolizumab in Patients with Metastatic Pancreatic Cancer

Status: Recruiting
Phase of Trial: Phase II

Latest Information Update: 30 Mar 2017

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Motixafortide (Primary) ; Pembrolizumab (Primary)
  • Indications Pancreatic cancer
  • Focus Therapeutic Use

    • Most Recent Events

    • 23 Mar 2017 According to a BioLineRx media release, partial results are expected in H2 2017 and top-line results are expected in H2 2018.
    • 30 Jan 2017 New trial record
    • 17 Jan 2017 According to a BioLineRx media release, Dr. David Fogelman, from MD Anderson Cancer Center, is the principal investigator of the trial

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top